Neumora Therapeutics, Inc. filed a Form 8-K on October 30, 2026, disclosing that it received a written notice from Nasdaq on October 26, 2026, indicating the company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market.

Key Highlights

  • Notice received October 26, 2026: Nasdaq informed Neumora Therapeutics in writing that its common stock does not meet the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1).
  • 180-day cure period: The company has until April 26, 2027, to regain compliance, per Nasdaq Listing Rule 5810(c)(3)(A).
  • Compliance threshold: To cure the deficiency, the closing bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days during the 180-day period.
  • Potential transfer option: If not in compliance by April 26, 2027, the company may apply to transfer to The Nasdaq Capital Market for additional time, subject to meeting continued listing requirements and paying an application fee.
  • Reverse stock split considered: The company disclosed it is considering options including "effecting a reverse stock split of its common stock" to resolve the noncompliance.
  • No assurance of compliance: According to the filing, "there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria."

Neumora Therapeutics Discloses Nasdaq Minimum Bid Price Deficiency and Cure Timeline

According to the Form 8-K filed with the SEC on October 30, 2026, Neumora Therapeutics, Inc. (NASDAQ:NMRA) received a written notice from The Nasdaq Stock Market LLC on October 26, 2026, stating that the company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum closing bid price of $1.00 per share for continued listing on The Nasdaq Global Select Market. The filing notes that this notice does not result in the immediate delisting of the company's common stock.

The company disclosed that it has a 180-calendar-day period, running through April 26, 2027, to regain compliance. Compliance can be achieved if the closing bid price of the common stock meets or exceeds $1.00 per share for at least ten consecutive business days within that window. If the company does not meet this threshold by the deadline, the filing states it may be eligible for additional time by applying to transfer its listing to The Nasdaq Capital Market, provided it satisfies all other initial listing standards for that market except the minimum bid price requirement, and pays an application fee.

The filing states that the company "intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance," including the possibility of a reverse stock split. Should the company fail to regain compliance within all applicable periods, Nasdaq would provide notice that the common stock is subject to delisting, at which point the company would have the right to appeal, though the filing cautions that no assurance can be given that any appeal would be successful. The 8-K was signed by Michael Milligan, Chief Financial Officer of Neumora Therapeutics, Inc.

What Was Disclosed

Neumora Therapeutics disclosed receipt of a Nasdaq non-compliance notice for failing to meet the $1.00 minimum bid price requirement, outlined a 180-day cure window ending April 26, 2027, and noted that a reverse stock split is among the options under consideration.